The Top 5 Biosimilars Articles for the Week of December 11

The Center for Biosimilars Staff

The Center for Biosimilars® recaps the top 5 articles for the week of December 11.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of December 11.

Number 5: Industry trade and lobbying group PhRMA sued California state officials in federal court over the state’s new drug pricing law, which the group calls “unprecedented and unconstitutional.”

Number 4: In a new comment letter, the American College of Rheumatology praised the FDA for considering ways to reduce regulatory burden, but called on the FDA to focus on 6 minimum components of review and oversight for biosimilars.

Number 3: The federal circuit ruled in Amgen v Sandoz that state law cannot compel drug makers to comply with the so-called patent dance.

Number 2: The FDA has granted final approval to the first short-acting follow-on insulin product, Sanofi’s Admelog.

Number 1: The FDA has approved Pfizer’s second infliximab biosimilar, Ixifi.

Finally, last week, our e-newsletter asked whether you think the United States should follow the European Commission’s lead in requiring industry to produce consensus documents on biosimilars. To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.